Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

Abstract

This article summarizes the results of international randomized VISTA trial: bortezomib plus melphalan-prednisone is superior to melphalan-prednisone alone in patients with newly diagnosed multiple myeloma who were ineligible for high-dose therapy.

Keywords

• multiple myeloma
• VISTA trial
• treatment
• therapy results